Hendrik C. Groenewegen a , Geanina Onuta c , Maaike Goris a , André Zandvoort c , Felix Zijlstra b , Wiek H. van Gilst a , Jan Rozing c , Bart J.G.L. de Smet a , Anton J.M. Roks a , Jan-Luuk Hillebrands c
23 April 2008
Objective: To determine the contribution of bone marrow (BM)-derived cells in in-stent restenosis (ISR) and transplant arteriosclerosis (TA). Methods: Non-transgenic rats WT F344<sup>TG</sup> (n = 3) received stent implantation 6 weeks after lethal total body irradiation and suppletion with bone marrow from a R26-hPAP transgenic rat. After 4 weeks the abdominal aortas were harvested, the stent was quickly removed, the abdominal aorta was snap-frozen in liquid nitrogen and 5 µm cryosections for stainings were cut. Additionally, DA aortic allografts were transplanted into WT F344<sup>TG</sup> (n = 3) and R26-hPAP<sup>WT</sup> (n = 3) BM-chimeric recipients. Immunohistochemistry (hPAP staining) and immunofluorescence (hPAP, α-SMA and OX1) was performed on all sections. Results: Few hPAP-positive cells were observed in the neointima. Double stainings of hPAP-positive areas showed no α-SMA colocalization; OX-1 did show colocalization. Conclusions: Non-BM-derived cells are the predominant source of neointimal cells in ISR and TA. Vascular wall-derived progenitor cells may rather be the source of SMCs that contribute to ISR and TA, which may have implications for our quest for new therapeutic targets to treat these vasculopathies.